



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C07C 311/20, A61K 31/215	A1	(11) International Publication Number: WO 98/16506 (43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/18170 (22) International Filing Date: 8 October 1997 (08.10.97) (30) Priority Data: 08/729,359 16 October 1996 (16.10.96) US (71) Applicant: AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940-0974 (US). (72) Inventors: LEVIN, Jeremy, Ian; 190 Treetop Circle, Nanuet, NY 10954 (US). ZASK, Arie; 200 Central Park South, New York, NY 10019 (US). GU, Yansong; 82 North Magnolia Avenue, Pearl River, NY 10965 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Cor- poration, One Campus Drive, Parsippany, NJ 07054 (US) et al.	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>	

(54) Title: BETA-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS

(57) Abstract

The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF- α converting enzyme (TACE, tumor necrosis factor- α converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease,

proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by formula (1) where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A where: A is a 5 to 7 membered, monocyclic, non-aromatic heterocyclic ring having from 1 to 2 heteroatoms independently selected from N, O, and S, optionally substituted by R¹, R², R³ and R⁴; a -C₃-C₇-cycloalkyl containing 0-2 double bonds and optionally substituted with R¹, R², R³ and R⁴; or -CHR⁵=CHR⁶-; and Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are described in the specification, and the pharmaceutically acceptable salts thereof, and the optical isomers and diastereomers thereof.



(1)